CD40 and plasma cell myeloma: Lucatumumab (HCD122; CHIR-12.12), a fully human anti-CD40 mAb, was shown to cause lysis of CD40+ (but not CD40-) myeloma cells via ADCC [64], leading to a phase I trial as monotherapy in RRMM patients (NCT00231166).